Procter & Gamble Work in process decreased by 3.3% to $1.01B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.6%, from $879.00M to $1.01B. Over 4 years (FY 2021 to FY 2025), Work in process shows an upward trend with a 8.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $719.00M | $769.00M | $766.00M | $837.00M | $856.00M | $898.00M | $946.00M | $966.00M | $956.00M | $972.00M | $962.00M | $971.00M | $929.00M | $921.00M | $879.00M | $957.00M | $1.01B | $1.04B | $1.01B |
| QoQ Change | — | +7.0% | -0.4% | +9.3% | +2.3% | +4.9% | +5.3% | +2.1% | -1.0% | +1.7% | -1.0% | +0.9% | -4.3% | -0.9% | -4.6% | +8.9% | +5.7% | +2.9% | -3.3% |
| YoY Change | — | — | — | — | +19.1% | +16.8% | +23.5% | +15.4% | +11.7% | +8.2% | +1.7% | +0.5% | -2.8% | -5.2% | -8.6% | -1.4% | +8.9% | +13.0% | +14.6% |
| % of Inventories | 12.0% | 12.2% | 11.5% | 11.8% | 12.4% | 11.8% | 12.5% | 12.9% | 13.5% | 13.7% | 13.5% | 13.7% | 13.2% | 12.6% | 12.5% | 12.9% | 13.4% | 13.3% | 12.9% |
| Share Change | — | +0.2pp | -0.7pp | +0.3pp | +0.6pp | -0.5pp | +0.7pp | +0.4pp | +0.6pp | +0.1pp | -0.2pp | +0.3pp | -0.5pp | -0.6pp | -0.1pp | +0.4pp | +0.5pp | -0.1pp | -0.4pp |
We use cookies for analytics. See our Privacy and Cookie Policy.